About kura oncology inc. - KURA
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
KURA At a Glance
Kura Oncology, Inc.
4930 Directors Place
San Diego, California 92121
| Phone | 1-858-500-8800 | Revenue | 53.88M | |
| Industry | Biotechnology | Net Income | -173,983,000.00 | |
| Sector | Health Technology | Employees | 192 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
KURA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.928 |
| Price to Book Ratio | 1.647 |
| Price to Cash Flow Ratio | 5.59 |
| Enterprise Value to EBITDA | -0.206 |
| Enterprise Value to Sales | 0.736 |
| Total Debt to Enterprise Value | 0.418 |
KURA Efficiency
| Revenue/Employee | 280,640.625 |
| Income Per Employee | -906,161.458 |
| Receivables Turnover | 8.833 |
| Total Asset Turnover | 0.072 |
KURA Liquidity
| Current Ratio | 9.463 |
| Quick Ratio | 9.463 |
| Cash Ratio | 9.241 |
KURA Profitability
| Gross Margin | 98.426 |
| Operating Margin | -358.545 |
| Pretax Margin | -319.145 |
| Net Margin | -322.89 |
| Return on Assets | -23.36 |
| Return on Equity | -42.91 |
| Return on Total Capital | -40.439 |
| Return on Invested Capital | -41.488 |
KURA Capital Structure
| Total Debt to Total Equity | 4.012 |
| Total Debt to Total Capital | 3.857 |
| Total Debt to Total Assets | 1.595 |
| Long-Term Debt to Equity | 2.927 |
| Long-Term Debt to Total Capital | 2.814 |
Kura Oncology Inc. in the News
Some Starbucks, Chipotle sites cut hours, limit seating over omicron
Chains such as Starbucks Corp. and Chipotle Mexican Grill Inc. said they are temporarily limiting operations at individual stores or regions as they face labor shortages and a rise in Covid-19 cases.